Stefanie Kutschmann, Good Manufacturing Practice Officer, Frankfurt, Germany

Stefanie Kutschmann, Good Manufacturing Practice Officer, Frankfurt, Germany

Stefanie Kutschmann, Good Manufacturing Practice Officer, Frankfurt, Germany

First quarter 2024 results

First quarter 2024 results will be reviewed by management during a conference call with the financial community on April 25th. The presentation will be followed by a Q&A session.

Our Latest News

Paris 2024 Partnership

March 28, 2024

The Meningitis Flag Awarded The Impact 2024 Label

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

Sanofi X Paris 2024

We’re proud to be premium partner of Paris 2024.

Science and sport aren’t that different. Just like athletes do, we overcome setbacks to keep moving forward, not just for ourselves, but for our patients, colleagues, families and friends.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

6

Therapeutic areas

83

Compounds in clinical development

28

Clinical trials in phase 3

Explore Career Opportunities

You'll be surprised what you can achieve at Sanofi. Discover your future here.

Our Latest Press Releases

April 17, 2024
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
March 22, 2024
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
March 11, 2024
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
February 24, 2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria